scholarly journals Angioleiomyolipomas in the renal sinus were misdiagnosed as renal cell carcinoma and renal pelvic carcinoma: Two case reports

2021 ◽  
Author(s):  
Ying-Jin Xu ◽  
Song-Hong Wu ◽  
Gen Li ◽  
Yong-Xia Zhao
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Case Reports ◽  
Renal Sinus

scholarly journals Clinical Significance of Tumor Size, Pathological Invasion Sites Including Urinary Collecting System and Clinically Detected Renal Vein Thrombus as Predictors for Recurrence in pT3a Localized Renal Cell Carcinoma

Diagnostics ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. 154 ◽  
Author(s):  
Takuto Shimizu ◽  
Makito Miyake ◽  
Shunta Hori ◽  
Kota Iida ◽  
Kazuki Ichikawa ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Recurrence Rate ◽  
Tumor Size ◽  
Renal Cell ◽  
Renal Vein ◽  
Recurrence Rates ◽  
Renal Sinus ◽  
Collecting System ◽  
Urinary Collecting System

The recent eighth tumor-node-metastasis (TMN) staging system classifies renal cell carcinoma (RCC) with perirenal fat invasion (PFI), renal sinus fat invasion (SFI), or renal vein invasion (RVI) as stage pT3a. However, limited data are available on whether these sites have similar prognostic value or recurrence rate. We investigated the recurrence rate based on tumor size, pathological invasion sites including urinary collecting system invasion (UCSI), and clinically detected renal vein thrombus (cd-RVT) with pT3aN0M0 RCC. We retrospectively reviewed 91 patients with pT3aN0M0 RCC who underwent surgical treatment. Patients with tumor size > 7 cm, UCSI, three invasive sites (PFI + SFI + RVI), and cd-RVT showed a significant correlation with high recurrence rates (hazard ration (HR) 2.98, p = 0.013; HR 8.86, p < 0.0001; HR 14.28, p = 0.0008; and HR 4.08, p = 0.0074, respectively). In the multivariate analysis, tumor size of >7 cm, the presence of UCSI, and cd-RVT were the independent predictors of recurrence (HR 3.39, p = 0.043, HR 7.31, p = 0.01, HR 5.06, p = 0.018, respectively). In pT3a RCC, tumor size (7 cm cut-off), UCSI, and cd-RVT may help to provide an early diagnosis of recurrence.

Kidney Transplantation From Donors with Resectable Renal Cell Carcinoma: Two Case Reports

2020 ◽  
Vol 52 (3) ◽  
pp. 737-739
Author(s):  
Murat Sevmis ◽  
Sinasi Sevmis ◽  
Sema Aktas ◽  
Mansur Khalilov ◽  
Mehmet Emin Demir
Keyword(s):  
Renal Cell Carcinoma ◽  
Kidney Transplantation ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Case Reports

Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma

2018 ◽  
Vol 71 (5) ◽  
pp. 467-471 ◽  
Author(s):  
Maria Rosaria Raspollini ◽  
Ilaria Montagnani ◽  
Rodolfo Montironi ◽  
Francesca Castiglione ◽  
Guido Martignoni ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Precision Medicine ◽  
Renal Cell ◽  
Clear Cell ◽  
Molecular Heterogeneity ◽  
Precision Oncology ◽  
Cell Renal Cell Carcinoma ◽  
Renal Sinus ◽  
The Moment

Clear cell renal cell carcinoma (ccRCC) is an heterogeneous tumour at architectural, cellular and molecular level, a reason why the 2014 International Society of Urological Pathology consensus recommended wide sampling of RCC masses to include at least 1 block/cm of tumour together with perpendicular sections of the tumour/perinephric fat interface and the tumour/renal sinus interface. Intratumoural molecular heterogeneity may be a limitation at the moment of defining precision medicine strategies based on gene mutation status. This study analyses the presence of any mutation of KRAS, NRAS, BRAF, PIK3CA, ALK, ERBB2, DDR2, MAP2K1, RET and EGFR genes in 20 tissue blocks from a case of ccRCC and its metastasis. We observed the presence of the mutation at pH1047R of PIK3CA gene in five samples of the tumour, while the remaining 15 samples did not show any mutation at PIK3CA or any other investigated gene. There is a great need to develop novel RCC sampling strategies to overcome tumour heterogeneity prior to define precision oncology strategies.

Leptomeningeal Metastases in Renal Cell Carcinoma at Initial Diagnosis: 2 Case Reports and Literature Review

2019 ◽  
Vol 37 (9) ◽  
pp. 501-505
Author(s):  
Manel Dridi ◽  
Wafa Bouleftour ◽  
Romain Rivoirard ◽  
Pierre Dal Col ◽  
Julien Langrand-Escure ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Literature Review ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Case Reports ◽  
Leptomeningeal Metastases ◽  
Initial Diagnosis

INVASION OF RENAL SINUS FAT NEGATIVELY IMPACTS SURVIVAL IN pT3a RENAL CELL CARCINOMA

2008 ◽  
Vol 179 (4S) ◽  
pp. 333-333
Author(s):  
Stephen A Poon ◽  
Joshua R Gonzalez ◽  
Alana M Murphy ◽  
Carl A Olsson ◽  
Mitchell C Benson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Sinus ◽  
Renal Sinus Fat

scholarly journals Prevalence of Malignancies in Patients With Primary Aldosteronism

2016 ◽  
Vol 101 (4) ◽  
pp. 1656-1663 ◽  
Author(s):  
K. Lang ◽  
K. Weber ◽  
M. Quinkler ◽  
A. S. Dietz ◽  
H. Wallaschofski ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Primary Aldosteronism ◽  
Renal Cell ◽  
Malignant Tumors ◽  
Single Case ◽  
Case Reports ◽  
Strong Association ◽  
Malignant Neoplasms

Abstract Context: Primary aldosteronism (PA) is the most common cause of secondary hypertension. Aldosterone excess can cause DNA damage in vitro and in vivo. Single case reports have indicated a coincidence of PA with renal cell carcinoma and other tumors. However, the prevalence of benign and malignant neoplasms in patients with PA has not yet been studied. Patients and Design: In the multicenter MEPHISTO study, the prevalence of benign and malignant tumors was investigated in 335 patients with confirmed PA. Matched hypertensive subjects from the population-based Study of Health in Pomerania cohort served as controls. Results: Of the 335 PA patients, 119 (35.5%) had been diagnosed with a tumor at any time, and 30 had two or more neoplasms. Lifetime malignancy occurrence was reported in 9.6% of PA patients compared to 6.0% of hypertensive controls (P = .08). PA patients with a history of malignancy had higher baseline aldosterone levels at diagnosis of PA (P = .009), and a strong association between aldosterone levels and the prevalence of malignancies was observed (P = .03). In total, 157 neoplasms were identified in the PA patients; they were benign in 61% and malignant in 25% of the cases (14% of unknown dignity). Renal cell carcinoma was diagnosed in five patients (13% of all malignancies) and was not reported in controls. Conclusion: Compared to hypertensive controls, the prevalence of malignancies was positively correlated with aldosterone levels, tended to be higher in PA patients, but did not differ significantly.

scholarly journals High-Grade Carcinomas Involving the Renal Sinus: Report of a Case and Review of the Differential Diagnosis and Immunohistochemical Expression

2012 ◽  
Vol 136 (8) ◽  
pp. 907-910 ◽  
Author(s):  
Allison Young ◽  
Lakshmi P. Kunju
Keyword(s):  
Renal Cell Carcinoma ◽  
Differential Diagnosis ◽  
Urinary Tract ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Collecting Duct ◽  
Upper Urinary Tract ◽  
High Grade ◽  
Renal Sinus

We report the case of a high-grade carcinoma involving the kidney in a young male with renal vein thrombosis and review the differential diagnosis and immunohistochemical workup. High-grade neoplasms involving the renal sinus include collecting duct carcinomas (CDCs), renal medullary carcinomas (RMCs), invasive high-grade urothelial carcinoma (UC) of the upper urinary tract, clear cell renal cell carcinoma, and type 2 papillary renal cell carcinoma. Distinguishing UC from CDC and RMC is problematic in small biopsy samples. The diagnosis of CDC (a rare, aggressive subtype of renal cell carcinoma) is challenging and requires the exclusion of UC. Renal medullary carcinoma is characterized by an appropriate clinical setting and consistent loss of nuclear expression of integrase interactor 1 (INI-1). A panel consisting of p63, paired box gene 8 (PAX8), and INI-1 is most optimal in distinguishing UC from CDC and RMC. A subset of urothelial carcinoma of upper urinary tract may be positive with PAX8.

scholarly journals Molecular targeted therapies of renal cell carcinoma considering life stage of the patient: Two case reports

2018 ◽  
Author(s):  
Hisashi Takeuchi ◽  
Naoto Tokuyama ◽  
Isao Kuroda ◽  
Teiichiro Aoyagi
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Case Reports ◽  
Life Stage ◽  
Molecular Targeted Therapies
Sign in / Sign up

Export Citation Format

Share Document